TABRECTA® (capmatinib) tablets | Non-US Health Care Providers

MET, mesenchymal-epithelial transition; mNSCLC, metastatic non-small cell lung cancer.

Patients with METex14 face a poor prognosis^1-3

TABRECTA delivered powerful and sustained overall responses⁴

Testing is critical in mNSCLC treatment planning

References

Hsu F, De Caluwe A, Anderson D, Nichol A, Toriumi T, Ho C. Patterns of spread and prognostic implications of lung cancer metastasis in an era of driver mutations. Curr Oncol. 2017;24(4):228-233.
Awad MM, Leonardi GC, Kravets S, et al. Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis. Lung Cancer. 2019;133:96-102.
Awad MM, Leonardi GC, Kravets S, et al. Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis. Supplementary Table 2. Lung Cancer (suppl). doi.org/10.1016/j.lungcan.2019.05.011.
Tabrecta National Product Information. Novartis Pharma AG; 2021.